These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8491246)

  • 21. Effect of nifedipine on plasma catecholamines in man at rest and during exercise.
    Defer G; Guezennec YC; Lhoste F
    Eur J Clin Pharmacol; 1986; 30(6):727-9. PubMed ID: 3533568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro susceptibility of Helicobacter pylori to nitecapone.
    Rautelin H; Renkonen OV; Kosunen TV
    Eur J Clin Microbiol Infect Dis; 1992 Mar; 11(3):274-5. PubMed ID: 1597212
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of eprosartan on catecholamines and peripheral haemodynamics in subjects with insulin-induced hypoglycaemia.
    Christensen M; Ibsen H; Worck R
    Clin Sci (Lond); 2005 Feb; 108(2):113-9. PubMed ID: 15383007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Failure of chronic theophylline therapy to alter circulating catecholamines.
    Whyte KF; Addis GJ; Whitesmith R; Reid JL
    Eur J Respir Dis; 1987 Apr; 70(4):221-8. PubMed ID: 3582518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462).
    Laihinen A; Rinne JO; Rinne UK; Haaparanta M; Ruotsalainen U; Bergman J; Solin O
    Neurology; 1992 Jan; 42(1):199-203. PubMed ID: 1734304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The equine metabolism of the catechol-O-methyltransferase enzyme inhibitor nitecapone.
    Stanley S; Deng D; Van den Berg K; Foo HC
    Drug Test Anal; 2022 May; 14(5):929-935. PubMed ID: 34545698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of ascorbate in protection by nitecapone against cardiac ischemia-reperfusion injury.
    Haramaki N; Stewart DB; Aggarwal S; Kawabata T; Packer L
    Biochem Pharmacol; 1995 Sep; 50(6):839-43. PubMed ID: 7575646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors.
    Vieira-Coelho MA; Gomes P; Serrão MP; Soares-da-Silva P
    Kidney Int; 2001 May; 59(5):1683-94. PubMed ID: 11318939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of St John's wort on catecholamine turnover and cardiovascular regulation in humans.
    Schroeder C; Tank J; Goldstein DS; Stoeter M; Haertter S; Luft FC; Jordan J
    Clin Pharmacol Ther; 2004 Nov; 76(5):480-9. PubMed ID: 15536462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease.
    Myllylä VV; Sotaniemi KA; Illi A; Suominen K; Keränen T
    Eur J Clin Pharmacol; 1993; 45(5):419-23. PubMed ID: 8112370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The part played by catechol-O-methyltransferase in the plasma kinetics of 3,4-dihydroxyphenylglycol and 3,4-dihydroxyphenylalanine in the anaesthetized rabbit.
    Friedgen B; Halbrügge T; Graefe KH
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Feb; 347(2):155-61. PubMed ID: 8474536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of catechol-O-methyltransferase inhibition on brain uptake of [18F]fluorodopa: implications for compartmental modelling and clinical usefulness.
    Léger G; Gjedde A; Kuwabara H; Guttman M; Cumming P
    Synapse; 1998 Dec; 30(4):351-61. PubMed ID: 9826227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nitecapone reduces development and symptoms of neuropathic pain after spinal nerve ligation in rats.
    Kambur O; Männistö PT; Pusa AM; Käenmäki M; Kalso EA; Kontinen VK
    Eur J Pain; 2011 Aug; 15(7):732-40. PubMed ID: 21216640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo assessment of catechol O-methyltransferase activity in rabbit skeletal muscle.
    Fujii T; Yamazaki T; Akiyama T; Sano S; Mori H
    Auton Neurosci; 2004 Apr; 111(2):140-3. PubMed ID: 15182744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of a catechol-O-methyltransferase inhibitor, nitecapone, in human plasma and urine by liquid chromatography.
    Wikberg T; Taskinen J
    J Pharm Biomed Anal; 1991; 9(1):59-64. PubMed ID: 2043724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of handling or immobilization on plasma levels of 3,4-dihydroxyphenylalanine, catecholamines, and metabolites in rats.
    Kvetnanský R; Goldstein DS; Weise VK; Holmes C; Szemeredi K; Bagdy G; Kopin IJ
    J Neurochem; 1992 Jun; 58(6):2296-302. PubMed ID: 1573408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antioxidant properties of nitecapone (OR-462).
    Suzuki YJ; Tsuchiya M; Safadi A; Kagan VE; Packer L
    Free Radic Biol Med; 1992 Nov; 13(5):517-25. PubMed ID: 1334029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of COMT induces dopamine-dependent natriuresis and inhibition of proximal tubular Na+,K+-ATPase.
    Eklöf AC; Holtbäck U; Sundelöf M; Chen S; Aperia A
    Kidney Int; 1997 Sep; 52(3):742-7. PubMed ID: 9291195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of extraneuronal amine transport systems for the removal of extracellular catecholamines in the rabbit.
    Friedgen B; Wölfel R; Russ H; Schömig E; Graefe KH
    Naunyn Schmiedebergs Arch Pharmacol; 1996; 354(3):275-86. PubMed ID: 8878057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.